Kura Oncology (NASDAQ:KURA) Shares Gap Down After Earnings Miss

Kura Oncology, Inc. (NASDAQ:KURA) gapped down before the market opened on Thursday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $8.55, but opened at $7.93. Kura Oncology shares last traded at $8.32, with a volume of 1,152,847 shares changing hands.

The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.50). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The firm had revenue of $17.34 million during the quarter, compared to analyst estimates of $34.71 million.

Key Headlines Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI commercial launch showing early uptake and payer access — Kura reported $2.1M of net product revenue from ~5 weeks of sales and says ~80% of private payers adopted label-aligned coverage within 90 days, supporting initial market access. Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Material collaboration milestone cashflows and patent protection — Kura recognized milestone payments (including a $135M milestone upon product delivery and two $30M payments tied to pivotal trial dosing) and has Orange Book-listed patents to 2044, bolstering near-term liquidity and long-term exclusivity. Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Advancing pivotal trials and 2026 milestone cadence — KOMET‑017 frontline Phase 3 trials are underway and multiple readouts/combinations (AML and solid tumors) are expected across 2026, presenting several potential value inflection points. Kura Oncology anticipates $7B AML opportunity as KOMZIFTI launches and combination strategies advance
• Neutral Sentiment: Analyst sentiment remains constructive but priced for growth — several firms maintain buy/overweight ratings and median price targets materially above current levels, indicating upside if commercial and trial execution meets expectations. Kura Oncology Reports Early Commercial Success for KOMZIFTI (ziftomenib) with Strong Initial Revenue and Payer Support
• Neutral Sentiment: Solid tumor and next‑generation programs progressing — darlifarnib expansions and next-gen menin inhibitor preclinical work diversify the pipeline but are longer-dated value drivers. Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Q4 results missed expectations — total revenue ($17.34M) and EPS (loss of $0.92) missed Street estimates; collaboration revenue declined vs. prior year and operating expenses rose due to commercialization spend. Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: Widening net loss and elevated commercialization costs — net loss jumped to $81M with higher R&D and SG&A, pressuring near-term profitability and making sustained revenue ramp critical to justify the increased burn. Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Safety profile and boxed warning may limit adoption — KOMZIFTI carries a boxed warning for differentiation syndrome and notable rates of QTc prolongation and other serious adverse events, which could constrain use and payer/provider comfort. Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Wedbush restated an “outperform” rating and issued a $38.00 price objective (up from $36.00) on shares of Kura Oncology in a report on Friday, November 14th. Barclays reaffirmed an “overweight” rating and set a $28.00 target price (up from $11.00) on shares of Kura Oncology in a report on Monday, November 24th. Leerink Partners set a $20.00 price target on shares of Kura Oncology and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and an average price target of $28.00.

Insider Activity

In other news, SVP Thomas James Doyle sold 7,142 shares of the firm’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $60,421.32. Following the completion of the sale, the senior vice president owned 145,167 shares in the company, valued at $1,228,112.82. This trade represents a 4.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Brian T. Powl sold 6,414 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $54,262.44. Following the sale, the insider directly owned 183,275 shares in the company, valued at approximately $1,550,506.50. The trade was a 3.38% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 59,794 shares of company stock valued at $537,176 in the last quarter. Insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. IFP Advisors Inc lifted its stake in shares of Kura Oncology by 115.3% in the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after purchasing an additional 1,284 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Kura Oncology by 392.8% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after purchasing an additional 3,072 shares during the last quarter. Allworth Financial LP raised its holdings in Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after buying an additional 1,553 shares during the period. PNC Financial Services Group Inc. lifted its position in Kura Oncology by 127.2% in the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after buying an additional 3,769 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after buying an additional 9,958 shares during the period.

Kura Oncology Trading Down 0.5%

The company has a market cap of $740.54 million, a PE ratio of -3.43 and a beta of 0.22. The company’s 50 day simple moving average is $8.79 and its two-hundred day simple moving average is $9.38. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.